Navigation Links
Orexigen® Therapeutics Reports Third Quarter Financial Results
Date:11/8/2011

bmission of an NDA; the therapeutic and commercial value of Contrave; Orexigen's ability to attract and retain key personnel; Orexigen's ability to raise and maintain sufficient capital; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Quarterly Report on Form 10-Q, which we intend to file with the Securities Exchange Commission this week and will be available from the SEC's website (www.sec.gov) and on our website (www.orexigen.com) under the heading "Investor Relations." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.Orexigen Therapeutics, Inc.Statements of Operations(In thousands, except per share amounts)(Unaudited)Three Months Ended Nine Months Ended September 30, September 30, 2011201020112010Revenues:Collaborative agreement $

857$

286$

2,571$

286License revenue 02297166Total revenues 8573083,542352Operating expenses:Research and development 1,5398,18611,23721,753General and administrative 3,9076,62415,87018,827Total operating expenses 5,44614,81027,10740,580Loss from operations (4,589)(14,502)(23,565)(40,228)Other income (expense):Interest income 92135101Interest expense -(165)(221)(501)Total other income (expense) 9(144)(186)(400)Net loss $

(4,580)$

(14,646)$

(23,751)$

(40,628)Net loss per share - basic and diluted $

(0.10)$

(0.31)$

(0.
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
2. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
3. Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
4. Orexigen® Therapeutics Announces Corporate Realignment
5. Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
6. Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring
7. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
9. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
11. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
(Date:7/10/2014)... Terascala, the industry leader in ... a former vice president of product management for Flexera ... of marketing. Terascala’s software when combined with leading compute ... highest performance and most reliable solutions for processing big ... channel expansion and broaden its product portfolio. His leadership ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., ... the relaunch of his highly informative blog, now named Stem ... What are Stem Cells ?” Dr. Harman’s purpose for ... the basics of stem cell therapy so that pet owners ... treatment when considering regenerative medicine. , A veterinarian by trade, ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... - AEterna Zentaris Inc. (NASDAQ: AEZS ... on endocrine therapy and oncology, announced today that ... offering of US$10 million of units comprised of ... certain institutional investors. AEterna Zentaris received net proceeds ...
... 24 Cancer therapies and diagnostics, including new technologies, enhanced ... testing, will be at the center of Cleveland Clinic,s 7th ... Summit will bring together more than 900 leaders from throughout ... cancer care, exchange perspectives and gain actionable insights. , ...
... & Industry Milestone of 1000 + Egg Donors , ... collaboration of egg donor agencies through out the United States, ... web-based collective of egg donors - has quickly become one ... more than one thousand diverse and multi-cultural egg donor candidates. ...
Cached Biology Technology:AEterna Zentaris Receives US$10 Million from Institutional Investors 2AEterna Zentaris Receives US$10 Million from Institutional Investors 32009 Medical Innovation Summit at Cleveland Clinic to Highlight the Latest Developments in Cancer Care 22009 Medical Innovation Summit at Cleveland Clinic to Highlight the Latest Developments in Cancer Care 3First-Ever Egg Donor Web Portal Becomes One of The Largest Resources for Aspiring Parents in the U.S. 2
(Date:7/11/2014)... China Researchers from Salk Institute for Biological Studies, ... evaluated the safety and reliability of the existing ... new method, TALEN-HDAdV, which could significantly increased gene-correction ... This study published online in Cell Stell ... stem cell-based gene therapy. , The combination of ...
(Date:7/11/2014)... Researchers from Ume University, Sweden, have explored two ... the reaction sequence leading to the formation of ... been published in the scientific journal Nature ... improving present day synthetic catalysts for water oxidation, ... devices for the direct storage of solar energy ...
(Date:7/11/2014)... has demonstrated that transplantation of mesenchymal stem cells can ... mouse models of Alzheimer,s disease (AD) and improve tissue ... Few studies are reported on the therapeutic effect of ... and on the effect on oxidative injury and neurogenesis ... and her team, School of Life Sciences, Tsinghua University, ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Molecular snapshots of oxygen formation in photosynthesis 2
... Botanists at Oregon State University have discovered that a ... at the same time it produces susceptibility to a ... has ever been observed in plants. The finding, ... of Sciences, may help scientists better understand the pathways ...
... coastal waters interfere with fish reproduction by disrupting the ... Texas at Austin Marine Science Institute has found. ... hypoxia, have increased dramatically in coastal waters throughout the ... result of increased run-off from human agricultural and industrial ...
... Saudi Arabia (August 30, 2007) Saudi Arabias King ... the Indian Institute of Technology, Bombay (IIT Bombay) ... 2, 2007, to work together to foster world-class programs that ... development in fundamental and applied chemical sciences for the benefit ...
Cached Biology News:Same gene protects from 1 disease, opens door to another 2Low oxygen in coastal waters impairs fish reproduction 2Saudi Arabia's KAUST and IIT, Bombay to Collaborate on Scientific Research 2
... Five cells (BTI-TN-5B1-4) derived from Trichoplusia ... shown to be capable of expressing ... proteins compared to other insect cells. ... features:- -Rapid doubling time as adherent cultures- Quick ...
... offers the most comprehensive, cost-effective solution ... have incorporated unprecedented quality into both ... includes proven detection chemistries and antibodies ... TechMate protocol. It also includes our ...
...
...
Biology Products: